COVID-19 Vaccine manufacturer Inovio With biologics manufacturers VGXI about DNA Disputes over intellectual property rights over the way vaccines are made are intensifying.

        Inovio Developed a method for targeting COVID-19 Vaccine candidate "INO-4800" . But with many other touted COVID-19 The same as the vaccine company, It doesn't have the capacity to mass produce products, You have to rely on outside companies. Due to Inovio The vaccine uses technology never before used in human vaccines, So there's limited information on how to do commercial production.

        VGXI is Inovio Long-term production partner, The two have cooperated 12 years. but VGXI Is not enough to achieve Inovio in 2020 Annual production 100 The goal of ten thousand doses, More impossible to achieve Inovio in 2021 Annual production 1 A hundred million doses of desire. Partly because, Inovio the DNA Plasmid products have never been approved for use.

        Reprinted from China Intellectual Property Network

        disclaimer: This website reprint articles are from the Internet, Does not represent the views of this website or confirm the authenticity of its content. If the source is mislabeled or the copyright of the article is involved, Please contact this website, This website will be corrected in due course, delete, thank you.